A Design Research on Formulation and Characterization of Gastro-retentive Tablet to Target Ulcer and Control Emesis

Main Article Content

Ms. Kiran Dudhat
Dr. Anjali Dhingani

Abstract

Targeted release of bilayer tablet for combination therapy of pantoprazole sodium and ondansetron hydrochloride for the treatment of gastric and duodenum ulcers associated with vomiting. In bilayer tablet release profiles may be modified by combining layers with various release patterns. Both Ondansetron hydrochloride and Pantoprazole sodium have short biological half-life and frequent administration may lead to patient incompliance. Thus, bilayer tablet is to be prepared imparting delayed release for pantoprazole sodium and sustained release for ondansetron hydrochloride.


Pantoprazole Na, an anti-ulcer drug, has several advantages compared to its analogues (e.g., omeprazole and lansoprazole) such as specific site of binding, greater stability in neutral pH environ-ment, and longer duration of action. Besides, it presents no potential to induce or inhibit the CYP 450. It is a more selective inhibitor of acid secretion than other proton pump inhibitors. Pantoprazole Na is absorbed in the intestine. It possesses an irritant effect on the stomach and is unstable under acidic conditions. Hence enteric delivery system is required. Such formulation would avoid the stomach's acidic exposure, delivering them to a basic pH environment (intestines pH 5.5 and above) and  give their desired action.


Ondansetron HCl is a potent, highly selective 5-HT3 receptor-antagonist. It is widely prescribed to control or prevents nausea and vomiting. It has narrow absorption window in stomach.  Once a day ondansetron HCl  gastroretentive  tablets  offer  better  patient compliance  through  less  frequent administration and thus would lower the cost of total  therapy. Hence, the focus of present work is to prepare and evaluate gastro retentive floating tablet of the ondansetron HCl to increase its residence time in to achieve prolonged therapeutic action.

Article Details

How to Cite
Dudhat, M. K., & Dr. Anjali Dhingani. (2022). A Design Research on Formulation and Characterization of Gastro-retentive Tablet to Target Ulcer and Control Emesis. International Journal of Pharmaceutical and Bio Medical Science, 2(5), 81–91. Retrieved from https://ijpbms.com/index.php/ijpbms/article/view/73
Section
Articles

References

I. Won DH, Park H, Ha ES, Kim HH, Jang SW, Kim MS. Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). International Journal of Pharmaceutics. 2021 Aug 10;605:120838.

II. Hwang KM, Nguyen TT, Seok SH, Jo HI, Cho CH, Hwang KM, Kim JY, Park CW, Rhee YS, Park ES. Swellable and porous bilayer tablet for gastroretentive drug delivery: Preparation and in vitro-in vivo evaluation. International Journal of Pharmaceutics. 2019 Dec 15;572:118783.

III. Maddiboyina B, Hanumanaik M, Nakkala RK, Jhawat V, Rawat P, Alam A, Foudah AI, Alrobaian MM, Shukla R, Singh S, Kesharwani P. Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension. Heliyon. 2020 Nov 1;6(11):e05459.

IV. Singh A, Das S, Gupta S, Ghosh S. The Challenges of Producing Bilayer Tablet: A Review. Journal of Drug Delivery and Therapeutics. 2021 Aug 15;11(4-S):171-5.

V. Rao SV, Priyanka B, Padmalatha K. Bilayer tablet technology: A novel approach. GSC Biological and Pharmaceutical Sciences. 2019;7(2).

VI. Qin C, Wu M, Xu S, Wang X, Shi W, Dong Y, Yang L, He W, Han X, Yin L. Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation. International Journal of Pharmaceutics. 2018 Jul 10;545(1-2):37-44.

VII. Gong L, Sun Y, Yu M, Gao Y, Zou M, Cheng G. Development and evaluation of compression coating gastro-floating tablet of alfuzosin hydrochloride for zero-order controlled release. Aaps Pharmscitech. 2018 Oct;19(7):3277-86.

VIII. Pinto LA, Corá LA, Rodrigues GS, Prospero AG, Soares GA, de Andreis U, de Arruda Miranda JR. Pharmacomagnetography to evaluate the performance of magnetic enteric-coated tablets in the human gastrointestinal tract. European Journal of Pharmaceutics and Biopharmaceutics. 2021 Apr 1;161:50-5.

IX. Maderuelo C, Lanao JM, Zarzuelo A. Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. European Journal of Pharmaceutical Sciences. 2019 Oct 1;138:105019.

X. Silva DA, Davies NM, Doschak MR, Al-Gousous J, Bou-Chacra N, Löbenberg R. Mechanistic understanding of underperforming enteric coated products: Opportunities to add clinical relevance to the dissolution test. Journal of Controlled Release. 2020 Sep 10;325:323-34.

XI. Karkossa F, Klein S. Individualized in vitro and in silico methods for predicting in vivo performance of enteric-coated tablets containing a narrow therapeutic index drug. European Journal of Pharmaceutics and Biopharmaceutics. 2019 Feb 1;135:13-24.

XII. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KR, Bhatt DL. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019 Aug 1;157(2):403-12.

XIII. Taskiran AS, Ergul M, Gunes H, Ozturk A, Sahin B, Ozdemir E. The effects of proton pump inhibitors (pantoprazole) on pentylenetetrazole-induced epileptic seizures in rats and neurotoxicity in the SH-SY5Y human neuroblastoma cell line. Cellular and Molecular Neurobiology. 2021 Jan;41(1):173-83.

XIV. Granholm A, Marker S, Krag M, Zampieri FG, Thorsen-Meyer HC, Kaas-Hansen BS, van der Horst IC, Lange T, Wetterslev J, Perner A, Møller MH. Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial. Intensive care medicine. 2020 Apr;46(4):717-26.

XV. Mille M, Engelhardt T, Stier A. Bleeding Duodenal Ulcer: Strategies in High-Risk Ulcers. Visceral Medicine. 2021;37(1):52-62.

XVI. Darmon, I., Rebibo, L., Diouf, M., Chivot, C., Riault, C., Yzet, T., Le Mouel, J.P. and Regimbeau, J.M., 2020. Management of bleeding peptic duodenal ulcer refractory to endoscopic treatment: surgery or transcatheter arterial embolization as first-line therapy? A retrospective single-center study and systematic review. European Journal of Trauma and Emergency Surgery, 46(5), pp.1025-1035.

XVII. Lingala S, Moore A, Kadire S, Shankar S, Das K, Howden CW. Unusual presentation of duodenal ulcer presenting with duodenal intussusception. ACG Case Reports Journal. 2018;5.

XVIII. Nakashima K, Ohdaira H, Kamada T, Kai W, Takahashi J, Nakaseko Y, Suzuki N, Yoshida M, Yamanouchi E, Suzuki Y. Usefulness of percutaneous transesophageal gastrotubing for gastric outlet obstruction secondary to duodenal ulcer, a case report. Radiology Case Reports. 2022 May 1;17(5):1431-4.

XIX. Gundu R, Pekamwar S, Shelke S, Shep S, Kulkarni D. Sustained release formulation of Ondansetron HCl using osmotic drug delivery approach. Drug development and industrial pharmacy. 2020 Mar 3;46(3):343-55.

XX. Teaima MH, El Mohamady AM, El-Nabarawi MA, Mohamed AI. Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery. Drug development and industrial pharmacy. 2020 May 3;46(5):751-61.

XXI. Rajawat GS, Belubbi T, Nagarsenker MS, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Parr A, Polli JE, Mehta M, Shah VP. Biowaiver monograph for immediate-release solid oral dosage forms: ondansetron. Journal of pharmaceutical sciences. 2019 Oct 1;108(10):3157-68.

XXII. Gong L, Sun Y, Yu M, Gao Y, Zou M, Cheng G. Development and evaluation of compression coating gastro-floating tablet of alfuzosin hydrochloride for zero-order controlled release. Aaps Pharmscitech. 2018 Oct;19(7):3277-86.

XXIII. Bakre LG, Ladele BA. Development and evaluation of gastroretentive ciprofloxacin floating tablets using Chrysophyllum albidum gum. Journal of Pharmacy Practice and Research. 2019 Jun;49(3):240-5.

XXIV. Bhagat A, Dangi SS, Ghatuary SK, Parkhe G. Formulation, development and evaluation of gastroretentive floating tablets of lovastatin using natural polymer. EAS J Pharm Pharmacol. 2019;1(4):92-8.

XXV. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole. Drugs. 2003 Jan;63(1):101-32.

XXVI. Wilde MI, Markham A. Ondansetron. Drugs. 1996 Nov;52(5):773